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reast cancer is the second most common cancer 
that occurs in women. More than 1.1 million 
cases are diagnosed annually and of these more 
than 410,000 patients die from breast cancer worldwide.1 
Malignant tumors usually express high levels of plasma 
membrane specific antigens, where some of these 
contribute to or promote the cancer phenotype through 
signaling and are considered as important therapeutic 
targets.2-4 Aberrant expression or activity of two 
members of the human epidermal growth factor family 
of receptors (HER), HER1 and HER2, have been 
connected to 20−30% of breast cancer cases.5 HER2 is a 
signaling tyrosine kinase receptor that causes increased 
cell proliferation, tumor invasiveness, accelerated 
angiogenesis and reduced apoptosis, ultimately 
translating into an aggressive disease, resistant to 
traditional systemic therapy, increased probability for 
recurrent disease and decreased survival.6,7 To date, only 
two drugs for targeted therapies of HER2-overexpressing 
tumors have been approved for human use. These 
include Tykerb (lapatinib) that targets the intracellular 
domain of HER2 and Herceptin (trastuzumab) which 
targets an extracellular part of HER2.8,9 There are 
complications with these therapies as well as with 
combination approaches.7,10 These include primary or 
intrinsic resistance to lapatinib as well as resistance and 
particularly cardiotoxicity with trastuzumab.10 Recent 
attempts have further exploited the endocytic properties 
of HER2 by tagging HER2 monoclonal antibodies to 
drug carriers such as liposomes.11 This approach not 
only creates multivalent antibody constructs capable of 
modulating malignant cell survival signaling pathways 
via extensive cross-linking of target/antibody complexes, 
but further allows for the delivery of chemotherapeutics 
and killer genes to HER2 expressing cells.11 Although 
promising results have been obtained, there are 
important nanoengineering problems involving construct 
design. These include complications with generation of 
sufficient functional surface antibody density without 
triggering immune responses (an important safety issue), 
antibody orientation and reduced antibody functionality 
(arising from chemical conjugation procedures). These 
concerns are not easily resolved even with the use of 
conventional antibody domains which lack the Fc region 
such as Fabs, diabodies, single chain variable fragments, 
bispecific antibodies and variable domains, especially 
when the antibody molecule possesses therapeutic 
activity.11-13  
The discovery of heavy chain antibodies has given rise 
to unprecedented opportunities in impacting cancer 
therapy.14 These unique form of camelid-derived 
antibodies lack the entire light chain and the CH1 domain 
and are only composed of a single variable domain 
termed VHH (Fig. 1). 
B 
S U M M A R Y A R T I C L E  I N F O 
Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a 
single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and 
isolated VHHs possess unique properties that enable them to excel conventional 
therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and 
therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture 
and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of 
VHH in design of new molecular, multifunctional particulate and immune cell-based 
systems for combating HER2+ breast cancer. 
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Fig. 1. Schematic representation of conventional and heavy-
chain antibodies. Unlike conventional antibodies, heavy-chain 
antibodies contain a single variable domain (VHH) and two 
constant domains (C H2 and CH3). Cloned and isolated VHH 
domain is highly stable and exhibit full antigen-binding capacity 
of the original heavy-chain antibody. There are ongoing efforts 
on phage display formats, library design and selection 
technologies for isolation of VHH domains against a diverse set 
of target antigens.15 
 
Recombinant VHHs are small (15-20 kDa) and strictly 
monomeric; they bind their target with nM affinity as 
well as with being stable in a broad pH and temperature 
ranges.16 Molecular manipulation is also easier with 
VHH; this facilitates the production of multivalent 
formats of monoclonal antibodies compared with 
conventional recombinant antibodies and their 
fragments, which is problematic due to aggregation and 
reduced affinity (i.e., mispairing of variable H and L 
domains). Moreover, VHH often binds to epitopes that 
are less immunogenic for conventional antibodies.16 
Another advantage is that they are well expressed in 
bacterial expression systems; hence, they are cheaper 
and easier than standard monoclonal antibodies to 
produce (at mg/L culture). Most importantly, heavy 
chain antibodies show 80% sequence homology to 
human VH fragments and therefore exhibit low 
immunogenicity.16 Collectively, these features make 
VHHs ideal small-sized functional candidates for (a) 
conjugation to macromolecular and nanoparticulate 
systems with optimized pharmacokinetic profiles, thus 
opening the path to new and sophisticated design 
solutions for targeted cancer therapy, and (b) T cell 
therapy which involves the adaptive transfer of tumor 
antigen specific T lymphocytes into cancer patients.17-21 
Recently, we provided the proof of concept that 
combination of a cancer specific VHH and gene 
therapeutics can exert dramatic effects on cancer cell 
recognition and cancer cell-specific killing, while 
offering no harm to non-target cells.19 This was done 
using a family of VHHs with specificities for 
DF3/Mucin 1 (MUC1) antigen, which is an aberrantly 
glycosylated glycoprotein over-expressed in a number of 
tumors including breast cancer in conjunction with 
transcriptional targeting of truncated Bid killer transgene 
for directed killing of MUC1 over-expressing tumor 
cells. To tackle the proposed problems in HER2-positive 
breast cancer and encouraged by unprecedented success 
of general VHH approach in cancer cell destruction, we 
(unpublished observations) and others have generated a 
panel of anti-HER2 VHHs.20 The availability of these 
VHH libraries offers a unique opportunity for paving the 
path towards molecular imaging and assessing 
intratumoural and intertumoural heterogeneity of HER2 
expression, combination therapies as well as design of 
multifunactional HER2-targeted macromolecular and 
particulate therapeutic/theranostic systems. Furthermore, 
by matching epitope-distinct binding, VHH-based 
protocols may be personalized thus improving 
therapeutic efficacy and outcome. However, the safety of 
these approaches must also be considered in relation to 
innate immunity.22-26 Another interesting strategy is 
HER2-directed oligoclonal T cell therapy, since VHH, 
by virtue of its small size, can endow great targeting 
ability to chimeric antigen receptor-engineered T cells, 
while minimizing adverse effects. The validity of this 
approach is also based on our recent observation with 
target-specific T cells bearing chimeric constructed 
receptors whose antigen binding moiety was comprised 
of a panel of camelid VHHs recognizing tumor-
associated glycoprotein-72 (a cell surface molecule with 
mucin-like characteristics and overexpressed on a range 
of tumors including breast and colorectal cancers).21 
These genetically engineered T cells expanded after 
antigen encounter and exerted potent tumor-specific 
functions. These approaches have the potential to reverse 
multiple tumors immune evasion mechanisms and avoid 
chimeric antigen receptor immunogenicity. Work on 
construction of genetically engineered T cells, bearing 
chimeric constructed receptors with HER2-specific 
camelid single domain antibodies as targeting agents, is 
ongoing and being tested both in vitro and validated in 
vivo animal models.  
Finally, recent advances in nanotechnology are expected 
to rapidly advance ‘patient-centric’ translational 
approach to cancer treatment.27 Potential examples 
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include micro-fluidic and micropatterning fabrication 
approaches (Fig. 2) for immune cell confinement in two- 
or three-dimensional (hydrogel-based) scaffolds. This 
could potentially allow parallel individual processing, 
training and selection of millions of T cells and even 
dendritic cells, thus opening new avenues for efficient 
planning and implementation of personalized immune-
cell therapies for cancer in general. 
 
 
Fig. 2. Schematic representation of a two-dimensional cell-
specific harvesting micro-fluidic platform. The device will allow 
processing of millions of cells through cell-specific immobilization 
at the micron-scale areas (square) covered with microcontacted 
printed ‘anchor’ ligands. Non-specific bound cells are removed 
by increasing the flow through the device. Attached cells may be 
modulated through appropriate micropatterning on conducting 
polymers and materials flow through the device, and cell 
responses may be monitored. Cell-specific harvesting may be 
achieved through the control of electrical signal. 
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